Melagatran-d11

Melagatran-d11 is the deuterium labeled Melagatran (HY-129056) . Melagatran is a direct and orally active inhibitor of thrombin, without interacting with any other enzymes in the coagulation cascade or fibrinolytic enzymes aside from thrombin. Melagatran does not require endogenous co-factors for its antithrombin effect and may help to alleviate some of the damaging effects of endotoxemia[1]. Melagatran has the potential to provide a rational approach in the prevention of arterial occlusion[2].

Product Specifications

UNSPSC

12352005

Target

Isotope-Labeled Compounds; Thrombin

Related Pathways

Metabolic Enzyme/Protease; Others

Field of Research

Cardiovascular Disease

Smiles

O=C(NCC1=CC=C(C=C1)C(N)=N)[C@@H]2CCN2C([C@@H](C3(C([2H])(C([2H])(C([2H])(C([2H])(C3([2H])[2H])[2H])[2H])[2H])[2H])[2H])NCC(O)=O)=O

Molecular Formula

C22H20D11N5O4

Molecular Weight

440.58

References & Citations

[1]Eriksson M, et al. Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock. Expert Opin Investig Drugs. 2000 May;9 (5) :1129-37.|[2]Mehta JL, et al. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. J Cardiovasc Pharmacol. 1998 Mar;31 (3) :345-51.